JCB logo
amgmicro.com
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online
doi:10.1083/jcb.1856iti2
The Journal of Cell Biology, Vol. 185, No. 6, 930-
The Rockefeller University Press, 0021-9525 $30.00
© Leslie
This Article
Right arrow Full Text (PDF, 565K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Leslie, M.
PubMed
Right arrow Articles by Leslie, M.
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

In This Issue

CD44's nuclear road trip



Figure 1
STAT3 (red) waits in the cytosol (left) but hitches a ride into the nucleus with CD44 (right).

Lee et al. reveal how a characteristic surface marker for cancer stem cells triggers abnormal growth. The protein makes a dash for the nucleus, picking up a couple of accomplices, including the transcription activator STAT3, along the way.

The surface receptor CD44 is overexpressed in many tumor types, including stomach cancer. Responding to neighboring cells and the extracellular matrix, the protein helps control everything from differentiation to survival. At the membrane, CD44 promotes signaling through the integrin proteins by corralling lipid rafts. Other scientists had previously shown that a snippet of CD44 could turn on genes in the nucleus. But whether the full-length protein could get there and what functions it might perform once it arrived were uncertain.

Lee et al. found that after stimulation, CD44 molecules evacuate the membrane of stomach cancer cells via the endocytic pathway. The proteins wend through the cytosol and eventually slip into the nucleus through a nuclear pore. A mutant protein lacking the nuclear localization sequence was locked out of the nucleus. But CD44 doesn't travel solo. On the way, it links up with STAT3 and another protein, p300. This meeting leads to STAT3's acetylation and activation. Once the combo reaches the nucleus, it latches onto the promoter for the cyclin D1 gene, which nudges the cell from the G1 phase into the S phase, thus speeding cell division. Other cancer-related surface receptors such as EGFR migrate into the nucleus. But they exert their effects through their enzymatic activity, whereas CD44 serves as a scaffold for other proteins, the researchers say. Still a mystery is how CD44's mobility relates to its role as a cancer stem cell marker.


References

Lee, J.-L., et al. 2009. J. Cell Biol. doi:10.1083/jcb.200812060.[CrossRef]



Mitch Leslie

mitchleslie{at}comcast.net


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Article

Acetylation and activation of STAT3 mediated by nuclear translocation of CD44
Jia-Lin Lee, Mei-Jung Wang, and Jeou-Yuan Chen
J. Cell Biol. 2009 185: 949-957. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF, 565K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Leslie, M.
PubMed
Right arrow Articles by Leslie, M.
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?


  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents